Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryanodex for Psychostimulant Drug-Induced Toxicity
NCT03189433Phase 2Terminated
- Sponsor
- Eagle Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dantrolene in Psychostimulant Toxicity, sponsored by Eagle Pharmaceuticals. Started Aug 2017; status: terminated.
02
Drugs
dantrolene
03
Conditions
Psychostimulant Toxicity
Beyond the preview
Go deeper on NCT03189433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189433.